ストックスクリーナーアプリを入手
1.60
2.44%
-0.04
アフターアワーズ：
2.58
0.98
+61.25%
前日終値:
$1.64
開ける：
$1.64
24時間の取引高:
13,274
Relative Volume:
0.39
時価総額：
$13.90M
収益：
-
当期純損益:
$-1.14M
株価収益率:
-3.8095
EPS:
-0.42
ネットキャッシュフロー:
$-2.11M
1週間 パフォーマンス:
-9.09%
1か月 パフォーマンス:
-6.43%
6か月 パフォーマンス:
-23.81%
1年 パフォーマンス:
-21.57%
1日の値動き範囲:
$1.59
$1.85
1週間の範囲:
$1.56
$1.94
52週間の値動き範囲:
$1.39
$2.58
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
名前
Pharmacyte Biotech Inc
セクター
電話
(917) 595.2850
住所
23046 AVENIDA DE LA CARLOTA, SUITE 600, LAGUNA HILLS
PMCB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| PMCB | 2.24 | 0 | 0 | 0 | 0 | 0.00 |
| GOODO | 22.16 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.141 | 297.56M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.16 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.61 | 114.98M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.95 | 63.87M | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc (PMCB) 最新ニュース
Malignant Ascites Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - openPR
Top 10 startups in In Vitro Diagnostics in Atlanta, United States in Oct, 2024 - Tracxn
Pharos Energy Advances Buyback, Reduces Share Capital - TipRanks
PPBT stock touches 52-week low at $5.89 amid market challenges By Investing.com - Investing.com South Africa
Proteomics International Laboratories (ASX:PIQ) presenting at the Pitt Street Research Life Sciences Conference 2024 - Stocks Down Under
POET Technologies (CVE:PTK) Trading Up 14.6% - MarketBeat
Small Cap Stocks: Plexus, Parkmead, Proton Motor - The Armchair Trader
PDS Biotechnology: Continuing The Holding Pattern (NASDAQ:PDSB) - Seeking Alpha
Tri Locum Partners LP Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Westwood Holdings Group Inc. Has $572,000 Stock Holdings in Patterson Companies, Inc. (NASDAQ:PDCO) - Defense World
Pre-IPO Zhejiang Taimei Medical Technology (PHIP Updates)Some Points Worth the Attention - Smartkarma
Texas Permanent School Fund Corp Sells 6,500 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Biotech stocks are an unappreciated way to profit from lower rates, Goldman says - Head Topics
Pancreatic Cancer Market Status Analysis, Scope, Trend, Capacity and Forecast 2024-2033 - Cauverynews
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2024 - Marketscreener.com
Encapsulated Live Cell Market to Record Rapid Revenue Growth from 2024 to 2031 - Elektrotransports.lv
Pancreatic Cancer Treatment Market Size Worth USD 10.53 - GlobeNewswire
Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider - GlobeNewswire Inc.
Financial Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) vs. INmune Bio (NASDAQ:INMB) - Defense World
PMCB stock touches 52-week low at $1.75 amid market challenges - Investing.com Australia
500: Something went wrong - Investing.com India
TNF Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
TNF Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc. - Marketscreener.com
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 1.9% - Defense World
Avant Technologies Announces Leadership Shake-Up and New CEO - TipRanks
Live Cell Encapsulation Market 2024 Growth Analysis by Market Es - WICZ
Live Cell Encapsulation Market 2024 Growth Analysis by Market Estimation, Manufacturers, Product Types Gross Margin and Forecast to 2030 - WICZ
Pancreatic Beta-Cell Protection Market Analysis and Revenue Prediction | ViaCyte, PharmaCyte Biotech, Boehringer ... - Economica
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 2.4% - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) Trading Down 2.4% - Defense World
Pancreatic Cancer Market is expected to surpass USD 7,541.09 Million by 2033, growing at a 13.5% annual rate | FMI Study - Market Research Blog
Pancreatic Cancer Market is expected to surpass USD 7,541.09 Million by 2033, growing at a 13.5% ann - PharmiWeb.com
Malignant Ascites Market Report 2034: Epidemiology, Pipeline The - News Channel Nebraska
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 2% - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) Stock Price Up 2% - Defense World
PharmaCyte Biotech's Diabetes Treatment: How Would It Work? - Yahoo Movies UK
Critical Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech - TipRanks
PharmaCyte Biotech announces $7 million strategic investment in MYMD - MSN
MyMD Pharmaceuticals Secures Strategic Investments - citybiz
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on ... - Winchester Herald Chronicle
Ascites Treatment Market Emerging Trends | Sequana Medical, BioVie, PharmaCyte Biotech - Motions Online
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business - Simply Wall St
Pharmacyte Biotech Inc (OTCMKTS:PMCB) Is At A Turning Point - Insider Financial
Femasys secures nearly $7M in funding from PharmaCyte - Mass Device
Ascites Market Exploring Market Trends and Growth: A 2030 Forecast Report | IMR Market Report - Newstrail
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology - Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer - Business Wire
PharmaCyte Biotech Announces Cash Tender Offer for up to 7750000 Shares at $3.25 Per Share - Business Wire
Trend Innovations Holding, Inc. Appoints Kenneth L. Waggoner as Chief Executive Officer - GlobeNewswire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan - Business Wire
Pharmacyte Biotech Inc (PMCB) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):